Drug intelligence / Profile preview

NBM-HD-1

Development stage: Preclinical
Lead developer: NBM
Modality: Small Molecules
Administration: Intraperitoneal

Overview

NBM-HD-1 is a novel small molecule histone deacetylase inhibitor (HDACi) developed by NatureWise Biotech & Medicals Corporation for the treatment of various cancers, including breast cancer and glioma. It is a semisynthetic derivative of propolin G, a natural compound isolated from Taiwanese green propolis. NBM-HD-1 exerts its anticancer effects by inhibiting histone deacetylases (HDACs), which leads to the hyperacetylation of histones and the subsequent modulation of genes involved in cell cycle regulation and tumor suppression. Preclinical evidence has shown that NBM-HD-1 effectively suppresses the growth of human breast cancer cells and rat glioma cells, and exhibits antitumor activity in breast cancer xenograft models.

Targets

HDAC1 (Histone Deacetylase 1)HDAC3 (Histone Deacetylase 3)HDAC6 (Histone deacetylase 6)

Beyond the preview

Go deeper on NBM-HD-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBM-HD-1.

Explore the full profile